ARIUS announces allowance of US patent for lead anti-cancer antibody
 

ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, announced today that the Company has received notice from the United States Patent and Trademark Office that a key patent for its lead anti-CD44 drug candidate will issue on August 7th, 2007, as US Patent Number 7,252,821.

More...